Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Research Report 2024(Status and Outlook)

Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Research Report 2024(Status and Outlook)



Report Overview:

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

The Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size was estimated at USD 205.43 million in 2023 and is projected to reach USD 388.41 million by 2029, exhibiting a CAGR of 11.20% during the forecast period.

This report provides a deep insight into the global Drugs for Duchenne Muscular Dystrophy (DMD) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Drugs for Duchenne Muscular Dystrophy (DMD) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Drugs for Duchenne Muscular Dystrophy (DMD) market in any manner.

Global Drugs for Duchenne Muscular Dystrophy (DMD) Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals

WaVe life Science

Market Segmentation (by Type)

Eteplirsen

Deflazacort

Ataluren

Market Segmentation (by Application)

Hospitals

Clinics

Home Care

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Drugs for Duchenne Muscular Dystrophy (DMD) Market

Overview of the regional outlook of the Drugs for Duchenne Muscular Dystrophy (DMD) Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Drugs for Duchenne Muscular Dystrophy (DMD) Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Drugs for Duchenne Muscular Dystrophy (DMD)
1.2 Key Market Segments
1.2.1 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Type
1.2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Drugs for Duchenne Muscular Dystrophy (DMD) Market Overview
2.1 Global Market Overview
2.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Competitive Landscape
3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Manufacturers (2019-2024)
3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Manufacturers (2019-2024)
3.3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Drugs for Duchenne Muscular Dystrophy (DMD) Sales Sites, Area Served, Product Type
3.6 Drugs for Duchenne Muscular Dystrophy (DMD) Market Competitive Situation and Trends
3.6.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Drugs for Duchenne Muscular Dystrophy (DMD) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Chain Analysis
4.1 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Drugs for Duchenne Muscular Dystrophy (DMD) Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Drugs for Duchenne Muscular Dystrophy (DMD) Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Type (2019-2024)
6.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Type (2019-2024)
6.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Price by Type (2019-2024)
7 Drugs for Duchenne Muscular Dystrophy (DMD) Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Sales by Application (2019-2024)
7.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Application (2019-2024)
7.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Growth Rate by Application (2019-2024)
8 Drugs for Duchenne Muscular Dystrophy (DMD) Market Segmentation by Region
8.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region
8.2 North America
8.2.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Sarepta Therapeutics
9.1.1 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
9.1.2 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
9.1.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
9.1.4 Sarepta Therapeutics Business Overview
9.1.5 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) SWOT Analysis
9.1.6 Sarepta Therapeutics Recent Developments
9.2 PTC Therapeutics
9.2.1 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
9.2.2 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
9.2.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
9.2.4 PTC Therapeutics Business Overview
9.2.5 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) SWOT Analysis
9.2.6 PTC Therapeutics Recent Developments
9.3 Pfizer
9.3.1 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
9.3.2 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
9.3.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
9.3.4 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) SWOT Analysis
9.3.5 Pfizer Business Overview
9.3.6 Pfizer Recent Developments
9.4 Bristol-Myers Squibb
9.4.1 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
9.4.2 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
9.4.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
9.4.4 Bristol-Myers Squibb Business Overview
9.4.5 Bristol-Myers Squibb Recent Developments
9.5 Italfarmaco
9.5.1 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
9.5.2 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
9.5.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
9.5.4 Italfarmaco Business Overview
9.5.5 Italfarmaco Recent Developments
9.6 Santhera Pharmaceuticals
9.6.1 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
9.6.2 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
9.6.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
9.6.4 Santhera Pharmaceuticals Business Overview
9.6.5 Santhera Pharmaceuticals Recent Developments
9.7 WaVe life Science
9.7.1 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
9.7.2 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
9.7.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
9.7.4 WaVe life Science Business Overview
9.7.5 WaVe life Science Recent Developments
10 Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Region
10.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast
10.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country
10.2.3 Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Region
10.2.4 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Drugs for Duchenne Muscular Dystrophy (DMD) by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2025-2030)
11.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2025-2030)
11.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Application (2025-2030)
11.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (Kilotons) Forecast by Application
11.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings